MoonLake Immunotherapeutics Prices Upsized $200M Offering for Sonelokimab Development
MLTX•MoonLake Immunotherapeutics has priced an upsized public offering of 9M Class A shares at $20 plus pre-funded warrants for 1M shares at $19.9999, generating approximately $200M before fees. Underwriters may buy 1.5M additional shares, with net proceeds to finance sonelokimab R&D, pre-commercialization and commercialization activities.
1. Offering Structure
MoonLake Immunotherapeutics has launched an upsized underwritten public offering of 9,000,000 Class A ordinary shares priced at $20 per share along with pre-funded warrants for up to 1,000,000 additional shares at $19.9999 each, exercisable immediately.
2. Underwriter Option and Closing
The underwriters have a 30-day option to purchase an additional 1,500,000 Class A shares at the public offering price less commissions, and the offering is expected to close on or about June 25, 2026, subject to customary conditions.
3. Proceeds Allocation
Gross proceeds of approximately $200 million before discounts and expenses will combine with existing cash to fund the research, development, pre-commercialization and potential commercialization of sonelokimab, as well as support general corporate activities.
4. Company Focus on Sonelokimab
MoonLake focuses on developing sonelokimab, a Nanobody® targeting IL-17A and IL-17F dimers for inflammatory diseases such as hidradenitis suppurativa and psoriatic arthritis, aiming to address large unmet treatment needs.
